Once-booming Texas border city known for affordability loses appeal among homebuyers
McAllen—a city of 146,000 people situated just a few miles north of the U.S.-Mexico border—experienced the sharpest decline in popularity among local homebuyers over the past six years, according to a new report from Realtor.com®.
Advertisement
The report analyzed the 100 largest U.S. metros for cross-market demand. Economists looked at views of Realtor.com listings, comparing how many out-of-town visitors were looking at homes in a city versus how many locals were shopping for properties elsewhere between April and June 2025.
According to the latest data, during the spring season, 65% of online home shopping traffic in McAllen went to listings outside the city, representing a 30% increase from 2019—the biggest jump among all the analyzed metros.
Realtor.com economist Jiayi Xu explains that McAllen's drop in homebuyer interest could be attributed to a combination of factors.
Advertisement
3 McAllen—a city of 146,000 people situated just a few miles north of the U.S.-Mexico border—experienced the sharpest decline in popularity among local homebuyers over the past six years.
Courtesy of City of McAllen
'Like many affordable markets, McAllen, TX, attracted new residents during the pandemic due to its low cost of living,' says Xu. 'However, as home prices rose and return-to-office trends resumed, some of that migration has started to reverse.'
Lower affordability, higher unemployment
In June 2025, the median home list price in McAllen was $274,950, up more than 38% from the same period in 2019.
Meanwhile, the unemployment rate in the border city reached 6% in May of this year, compared with 5.4% six years ago.
Advertisement
In light of rising home prices and shrinking job opportunities in McAllen, local homebuyers began casting covetous glances toward more busting nearby metros like Austin and San Antonio, where there is an abundance of high-paying work.
3 According to the latest data, during the spring season, 65% of online home shopping traffic in McAllen went to listings outside the city.
Realtor.com
According to the Realtor.com analysis, McAllen residents' out-of-market online home searches directed at Austin and San Antonio surged from just 4.8% and 16.1%, respectively, to 10.7% and 18.9% over the past six years.
Ironically, McAllen might be a victim of its own success, as rising home equity has likely enabled residents to relocate to higher-priced metros.
Advertisement
'Over the last six years, home prices in McAllen have climbed 65.6% on a price-per-square-foot basis, significantly increasing homeowner equity,' says Realtor.com senior economic research analyst Hannah Jones. 'This equity growth may be providing some local homeowners with the flexibility to pursue employment opportunities in other parts of Texas.'
3 Meanwhile, the unemployment rate in the border city reached 6% in May of this year, compared with 5.4% six years ago.
Google Maps
But according to Jones, it's not all bad news for McAllen, located just across the Rio Grande from Mexico—an area that has been at the center of the ongoing border crisis.
'While the 'border crisis' narrative could nudge some buyers or employers away from McAllen, there is no evidence of a mass exodus of population,' she says. 'The area's housing market remains stable, and its relative affordability means that the area sees strong demand from out-of-metro buyers.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
42 minutes ago
- Business Upturn
Global Dermal Fillers Market is Predicted to Reach ~USD 12 Billion by 2032
By GlobeNewswire Published on July 31, 2025, 22:00 IST New York, USA, July 31, 2025 (GLOBE NEWSWIRE) — Global Dermal Fillers Market is Predicted to Reach ~USD 12 Billion by 2032 | DelveInsight The demand for dermal fillers is influenced by several major factors. First, the global increase in cosmetic procedures is largely driven by an aging population and a heightened desire to preserve a youthful look, coupled with growing aesthetic awareness. Additionally, there is a notable trend toward minimally invasive cosmetic treatments because they offer greater convenience, quicker recovery, and lower costs compared to traditional surgical options. DelveInsight's Dermal Fillers Market Insights report provides the current and forecast market analysis, individual leading dermal fillers companies' market shares, challenges, dermal fillers market drivers, barriers, trends, and key market dermal fillers companies in the market. Key Takeaways from the Dermal Fillers Market Report As per DelveInsight estimates, North America is anticipated to dominate the global dermal fillers market during the forecast period. In the material segment of the dermal fillers market, the hyaluronic acid (HA) category accounted for the largest market share in 2024. Notable dermal fillers companies such as AbbVie Inc., Galderma, Merz Pharma, Tiger BioSciences, Teoxane SA, Crown Laboratories, Inc., Prollenium Medical Technologies, Inc., Johnson & Johnson Services, Inc., Anika Therapeutics, Inc., Fillmed, VIVACY Laboratories, Sinclair, Medytox, HUGEL, Inc., Ipsen Pharma, Evolus, Inc., Symatese, LG Chem, KORU Pharma Co., LTD., BIOPLUS CO., LTD., and several others are currently operating in the Dermal Fillers market. and several others are currently operating in the Dermal Fillers market. In February 2025, Crown Laboratories, Inc., a privately held global leader in skincare innovation, announced the successful acquisition of Revance Therapeutics, Inc., a pioneering biotechnology company specializing in dermal fillers. Through this acquisition, Crown significantly enhanced its product portfolio and expanded its global presence in the dermal fillers market, particularly with RHA Redensity™ and its range of RHA® 2, RHA® 3, and RHA® 4-based dermal fillers. a privately held global leader in skincare innovation, announced the successful acquisition of Revance Therapeutics, Inc., a pioneering biotechnology company specializing in dermal fillers. Through this acquisition, Crown significantly enhanced its product portfolio and expanded its global presence in the dermal fillers market, particularly with RHA Redensity™ and its range of RHA® 2, RHA® 3, and RHA® 4-based dermal fillers. In October 2024, Allergan Aesthetics, an AbbVie company, announced the national availability of JUVÉDERM® VOLUMA® XC for the treatment of temple hollowing. This hyaluronic acid (HA) filler is approved for addressing moderate to severe temple hollowing in adults over 21. As the leading HA dermal filler brand preferred by both patients and providers, the JUVÉDERM® Collection of Fillers now offers the broadest range of treatment indications to help patients achieve their aesthetic goals. To read more about the latest highlights related to the dermal fillers market, get a snapshot of the key highlights entailed in the Global Dermal Fillers Market Report Dermal Fillers Overview Dermal fillers are injectable substances used to restore volume, smooth out wrinkles, and enhance facial contours. Composed primarily of hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid, or polymethylmethacrylate beads, these fillers work by replenishing lost volume in the skin and stimulating collagen production. They are commonly used to treat areas such as the cheeks, lips, nasolabial folds, and under-eye hollows, providing a non-surgical alternative for facial rejuvenation. The effects of dermal fillers are temporary, lasting anywhere from six months to two years, depending on the type of filler and individual patient factors. The procedure is minimally invasive, typically performed in a clinical setting with little to no downtime. Local anesthesia or numbing agents may be applied to minimize discomfort during injection. While generally safe when administered by trained professionals, dermal fillers can have side effects, including swelling, bruising, redness, and in rare cases, complications like vascular occlusion or infection. Due to these risks, proper patient assessment and adherence to safety protocols are essential. Increasingly popular for their convenience and effectiveness, dermal fillers remain a leading option in cosmetic dermatology for individuals seeking subtle yet noticeable aesthetic improvements. Dermal Fillers Market Insights North America is expected to dominate the dermal fillers market in the coming years, supported by several critical factors. This leadership is largely driven by the growing number of cosmetic procedures, which are influenced by an aging population and a strong desire to maintain youthful looks. Additionally, the preference for minimally invasive aesthetic treatments, combined with a robust healthcare infrastructure, has accelerated market expansion. Rising awareness and widespread acceptance of cosmetic enhancements further reinforce this trend. Moreover, frequent product approvals and new launches from leading players continue to strengthen North America's market position. These dynamics are anticipated to maintain the region's dominance throughout the forecast period of 2025–2032. A key growth driver in the region is the increasing volume of aesthetic procedures, reflecting the rising demand for non-surgical treatments that deliver quick results with minimal recovery time. This surge is fueled by greater awareness, societal acceptance of cosmetic improvements, and a growing elderly population seeking effective anti-aging solutions. In addition, major industry players are actively investing in R&D to develop advanced dermal filler products tailored for regional needs. For instance, in June 2023, Galderma received FDA approval for Restylane® Eyelight, specifically designed to treat under-eye hollows in adults over 21. It is the first and only HA filler in the U.S. featuring NASHA® Technology to restore under-eye volume and deliver natural results. Similarly, in February 2022, Allergan Aesthetics, an AbbVie company, secured FDA approval for JUVÉDERM® VOLBELLA® XC for treating infraorbital hollows in adults over 21. This product also serves as a lip augmentation solution and helps correct perioral lines, enhancing overall facial aesthetics. Together, the growing demand for cosmetic procedures and strategic product innovations are fueling the dermal fillers market in North America, solidifying its status as a leading region in the global market. To know more about why North America is leading the market growth in the dermal fillers market, get a snapshot of the Dermal Fillers Market Outlook Dermal Fillers Market Dynamics The dermal fillers market is experiencing significant growth, driven primarily by the increasing demand for minimally invasive aesthetic procedures. Rising awareness about cosmetic enhancements and the desire for youthful appearances have fueled the adoption of dermal fillers across various demographics. Factors such as the aging global population, especially in developed economies, and growing disposable incomes in emerging markets have further contributed to market expansion. These procedures are preferred for their relatively quick recovery time and non-surgical nature, which aligns with the current trend toward less invasive treatment options. Technological advancements in dermal filler products have also played a crucial role in shaping market dynamics. Innovations in filler composition, including the introduction of hyaluronic acid-based and biostimulatory fillers, have improved safety profiles, longevity, and natural results. Moreover, ongoing research and development efforts by key players to develop fillers with longer-lasting effects and fewer side effects continue to enhance product appeal. These advancements have not only expanded the scope of applications but have also increased patient satisfaction, encouraging repeat procedures and contributing to market growth. Regulatory approvals and favorable reimbursement policies in certain regions further support the expansion of the dermal fillers market. However, stringent regulations in countries with established healthcare systems can act as barriers for new entrants. Additionally, the rise of medical tourism in countries like Thailand, India, and Mexico has created new growth opportunities for service providers and manufacturers, as patients seek affordable yet high-quality aesthetic treatments. Despite these positive trends, the dermal fillers market faces challenges such as the risk of complications, including allergic reactions and improper injections leading to vascular occlusion. Additionally, the availability of counterfeit or substandard products in some markets poses safety concerns and threatens consumer confidence. Competition from alternative aesthetic procedures like botulinum toxin injections and energy-based devices also adds pressure to the market. Nevertheless, continuous innovation, increasing social acceptance, and the growing influence of social media on beauty standards are expected to sustain robust growth in the coming years. Get a sneak peek at the dermal fillers market dynamics @ Dermal Fillers Market Trends Report Metrics Details Coverage Global Study Period 2022–2032 Dermal Fillers Market CAGR ~8% Dermal Fillers Market Size by 2032 ~USD 12 Billion Key Dermal Fillers Companies AbbVie Inc., Galderma, Merz Pharma, Tiger BioSciences, Teoxane SA, Crown Laboratories, Inc., Prollenium Medical Technologies, Inc., Johnson & Johnson Services, Inc., Anika Therapeutics, Inc., Fillmed, VIVACY Laboratories, Sinclair, Medytox, HUGEL, Inc., Ipsen Pharma, Evolus, Inc., Symatese, LG Chem, KORU Pharma Co., LTD., BIOPLUS CO., LTD., among others Dermal Fillers Market Assessment Dermal Fillers Market Segmentation Dermal Fillers Market Segmentation By Product Type: Biodegradable Fillers and Non-Biodegradable Fillers Dermal Fillers Market Segmentation By Route of Material: Hyaluronic Acid (HA), Calcium hydroxylapatite (CaHA), Poly-L-lactic acid (PLLA), Polymethylmethacrylate (PMMA), and Others Dermal Fillers Market Segmentation By Route of Gender: Male and Female Dermal Fillers Market Segmentation By End-User: Hospitals, Dermatology Clinics, and Others Dermal Fillers Market Segmentation By Geography : North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the dermal fillers market are set to emerge as the trendsetter explore @ Dermal Fillers Analysis Table of Contents 1 Dermal Fillers Market Report Introduction 2 Dermal Fillers Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Dermal Fillers Market Key Factors Analysis 6 Dermal Fillers Market Porter's Five Forces Analysis 7 Dermal Fillers Market Layout 8 Dermal Fillers Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the dermal fillers market by 2032? Click to get a snapshot of the Dermal Fillers Market Analysis Related Reports Aesthetic Implants Market Aesthetic Implants Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key aesthetic implants companies, including POLYTECH Health & Aesthetics GmbH, Sientra, Inc, Surgiform Innovative Surgical Products, GC Aesthetics, Dentsply Sirona, Institut Straumann AG, AVINENT, AbbVie, Establishment Labs S.A., Mentor (Johnson & Johnson Medical Ltd), 3M, Zimmer Biomet, Alpha Aesthetics, Symatese, Integra LifeSciences, Sebbin, IDEAL IMPLANT INCORPORATED, Lattice Medical, CEREPLAS, Guangzhou Wanhe Plastic Material Co Ltd, among others. Medical Aesthetic Devices Market Medical Aesthetic Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key medical aesthetic devices companies, including Johnson & Johnson, HansBioMed., AbbVie Inc., Sebbin, Sientra, Inc., POLYTECH Health & Aesthetics GmbH, Suneva Medical, Hanson Medical Inc., SurgiSil, Surgiform Technologies LLC, Alma Lasers, Candela Medical., Lumenis., Cutera., Sciton Inc, Merz Pharma GmbH & Bausch Health Companies Inc., Venus Concept., TRIA BEAUTY, Cynosure Inc., GALDERMA, among others. Aesthetic Thread Market Aesthetic Thread Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key aesthetic thread companies, including Aptos International Ltd, Intraline, Healux Corporation, Croma Pharma GambH, Les Encres Cosmetic Threads, W & O Medical Esthetics Gmbh, Hyundae Meditechh Co. Ltd., N-Finders Co., Ltd., Nova Threads, Savia medical, Metro Korea Co., Ltd., RIVER AESTHETICS, Spring Thread, RELIFE S.r.l., Sinclair, MINT™, PDO MAX, Promoitalia, EWELL Medical., illari Threads, among others. Aesthetic Lasers Market Aesthetic Lasers Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key aesthetic lasers companies, including Boston Scientific Corporation, Candela Medical, Lynton Lasers, Lutronic, Fotona, Alma Lasers, Sciton, Astanza Laser, Konmison, AMI INC., Lumibird Medical (Ellex), Cutera, biolitec® Holding GmbH & Co KG, Cartessa Aesthetics, Beagle E-Comm Private Limited, WON TECH Co., Ltd., Attikouris Enterprises Ltd., Aftab Forouzan Aria Company, SL LASERS, Reveal Lasers LLC, among others. Energy-Based Aesthetic Devices Market Energy-Based Aesthetic Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key energy-based aesthetic devices companies, including Alma Lasers, Candela Medical, Lumenis, Cutera, Hologic Inc., Sciton Inc., Merz Pharma GmbH & Bausch Health Companies Inc., Venus Concept, TRIA BEAUTY, Cynosure Inc., SharpLight Technologies Inc., Lutronic, Fotona, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
an hour ago
- Yahoo
Bargain Retail Is Booming. 3 Stocks to Buy to Capitalize on the Trend in 2025
Key Points TJX's off-price business is growing as it gobbles up liquidated inventories. Costco's warehouse clubs are still expanding and locking in more shoppers. Dollar Tree's divestment of Family Dollar could be a game-changer. These 10 stocks could mint the next wave of millionaires › The retail apocalypse -- which was caused by expanding e-commerce marketplaces, the decline of malls, and a shrinking middle class -- wiped out many retailers over the past decade. The Great Recession and the COVID-19 pandemic exacerbated that destructive downturn. However, many bargain retailers still thrived and expanded as their higher-priced peers retreated. According to Business Research Insights, the global discount retail market could continue to expand at a robust compound annual growth rate (CAGR) of 10.5% from 2025 to 2033. Let's take a look at three of those resilient bargain retailers -- TJX Companies (NYSE: TJX), Costco Wholesale (NASDAQ: COST), and Dollar Tree (NASDAQ: DLTR) -- and see why they could be great ways to capitalize on that secular trend in 2025. 1. TJX Companies TJX Companies, the parent company of TJ Maxx, HomeGoods, HomeSense, Marshalls, and Sierra Trading Post, is the world's largest off-price retailer. It operates over 5,000 stores and six e-commerce sites across nine countries, and it sells its products at 20% to 60% lower prices than its full-price peers do. TJX buys up liquidated inventories from struggling retailers at rock-bottom prices. That strategy helped it expand throughout the retail apocalypse, even as bigger retailers collapsed. It also frequently rotates its products to drive return visits and "treasure hunts" at its stores. From its fiscal 2015 to fiscal 2025 (which ended this February), TJX's revenue grew at a CAGR of 7%. Its year-end store count increased by 50%, its gross profit margin expanded from 28.5% to 30.6%, and its earnings per share (EPS) rose at a CAGR of 3%. From fiscal 2025 to fiscal 2028, analysts expect its revenue and EPS to grow at CAGRs of 6% and 9%, respectively. That resilience makes TJX one of the simplest ways to profit from the expansion of the off-price market and the contraction of the full-price market. Its stock still looks reasonably valued at 28 times this year's earnings, and it pays a decent forward dividend yield of 1.3%. 2. Costco Wholesale Costco is the world's largest warehouse club retailer. It can afford to sell its products at much lower margins than full-price retailers because it generates most of its profits from its higher-margin membership fees. It can keep growing as long as it keeps expanding, gaining more cardholders, and locking them in as it gradually raises those fees. From its fiscal 2014 to fiscal 2024 (which ended last September), Costco's annual revenue and EPS rose at CAGRs of 8% and 14%, respectively. Its number of year-end warehouses grew from 663 to 891 as its number of cardholders increased from 76 million to 137 million. It maintained a healthy global renewal rate of 90.5% in its latest quarter. From fiscal 2024 to fiscal 2027, analysts expect Costco's revenue and EPS to increase at CAGRs of 8% and 10%, respectively. That growth should be driven by its domestic and overseas expansion, its robust e-commerce sales, and its rising membership fees. Costco only pays a forward yield of 0.6% -- and its stock might seem pricey at 47 times next year's earnings -- but its evergreen strengths justify that premium valuation. 3. Dollar Tree Dollar Tree, which acquired Family Dollar in 2015, is the second-largest dollar store retailer in the U.S. after Dollar General. It mainly serves urban and suburban shoppers, while Dollar General opens more stores in rural areas. From its fiscal 2014 to fiscal 2024 (which ended this February), Dollar Tree's number of year-end stores (including Family Dollar) more than tripled from 5,367 to 16,774 as its revenue increased at a CAGR of 14%. Yet Dollar Tree racked up net losses over the past two years as Family Dollar's weak sales offset the strength of its namesake banner. It tried to squeeze more value from the brand by opening "combo stores" under both banners, but that strategy didn't pay off. That's why it wasn't surprising when Dollar Tree finally divested all of its Family Dollar stores this year. By selling Family Dollar, Dollar Tree freed up a lot more cash to strengthen its namesake banner. It plans to renovate more of its stores, roll out its new tiered pricing strategy (which broadens its price range up to $7) across more locations, and attract higher-income shoppers. Analysts expect its revenue to decline 38% in fiscal 2025 as it sells Family Dollar, but they still see its revenue growing at a CAGR of 6% over the following two years. They also see its EPS turning positive again this year and growing at a CAGR of 13% through fiscal 2027. Its stock still looks reasonably valued at 21 times this year's earnings, and it could attract a lot more investors once it demonstrates that its newly streamlined business can keep growing. Should you buy stock in TJX Companies right now? The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $633,452!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,083,392!* Now, it's worth noting Stock Advisor's total average return is 1,046% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Leo Sun has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Costco Wholesale and TJX Companies. The Motley Fool has a disclosure policy. Bargain Retail Is Booming. 3 Stocks to Buy to Capitalize on the Trend in 2025 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
an hour ago
- Business Insider
An investing guru explains why you shouldn't cash out if you think a crash is coming
The chipmaker's share price has surged 12-fold since the start of 2023, supercharging its valuation to an unmatched $4.4 trillion. Malkiel told Business Insider that he's happy to have owned the stock as part of the S&P 500, as the idea of investing directly in Nvidia a couple of years ago — when it was trading at more than 100 times forward earnings — "would have scared the hell out of me." Malkiel, 92, the chief investor of Wealthfront, a robo-advisor with over $80 billion of client assets, warned against selling stocks with a plan to reinvest once prices retreat from all-time highs. The retired Princeton economics professor — a renowned advocate of passive investing — told BI the "biggest unforced error" that investors make is trying to time when to sell and when to get back in, adding it is "virtually impossible" to get both right. Malkiel said he understands people feel pressure to sell when stocks are dropping and they're watching their life savings shrink. "Boy, I know the emotions, I know how hard it is," he said. But cashing out is "invariably the wrong decision," he added. Malkiel argued this in a Thursday letter titled "Don't Miss the Market Rebound," cowritten with Wealthfront's investment-research boss, Alex Michalka. In the letter, Malkiel said that the 10 best days for US stocks in the last 50 years closely followed significant market declines. Five were during the global financial crisis, three were at the height of the COVID-19 pandemic, and one was after Black Monday. The final and third-best day on the list was April 9 this year, when the S&P rebounded 10% to register its largest one-day gain in 17 years. The index had fallen 12% between April 2 and April 8 in reaction to Donald Trump unveiling his tariff plans. Emotions, concentration, and memes Malkiel recommended that people invest part of every paycheck into a diversified index fund, a strategy called " dollar-cost averaging." This "set it and forget it" approach minimizes advisory and transaction fees, and helps investors avoid making hasty decisions and missing out on returns, he said. He criticized leveraged ETFs that promise a multiplied return on a stock or index. "These are just sort of pure speculative pieces of paper, and that bothers me," he said. Meme stocks, which are having a renaissance, "invariably lead you astray," Malkiel said. "Like any gambler, you can have some hits and make some money, but over the long run, you're going to lose money."
